Biomarkers for the early detection of cancer in the general population have to perform with high sensitivity and specificity in order to prevent the costs associated with over-diagnosis. There are only a few current tissue or blood markers that are recommended for generalized cancer screening. Despite the recognition that combinations of multiple biomarkers will likely improve their utility, biomarker panels are usually limited to a single class of molecules. Tissues and body fluids including plasma and serum contain not only proteins, DNA and microRNAs that are differentially expressed in cancers but further cancer specific information might be gleaned by comparing different classes of biomolecules. For example, the level of a certain microRNA might be related to the level of a particular protein in a cancer specific manner. Proteins might have cancer-specific post-translational modifications (e.g., phosphorylation or glycosylation) or lead to the generation of autoantibodies. Most currently approved biomarkers are glycoproteins. Autoantibodies can be produced as a host’s early surveillance response to cancer-specific proteins in pre-symptomatic and pre-diagnostic stages of cancer. Thus, measurement of the level of a protein, the level of its glycosylation or phosphorylation and whether autoantibodies are produced to it can yield multi-dimensional information on each protein. We consider specific proteins that show consistent cancer-specific changes in two or three of these measurements to be “hybrid markers”. We hypothesize these markers will suffer less variation between different individuals since one component can act to “standardize” the other measurement. As a proof of principle, a 180 plasma sample set consisting of 120 cases (60 colon cancers and 60 adenomas) and 60 controls were analyzed using our high-density antibody array for changes in their protein, IgG-complex and sialyl-Lewis A (SLeA) modified proteins. At p < 0.05, expression changes in 1,070 proteins, 49 IgG-complexes (11 present in the protein list) and 488 Lewis X-modified proteins (57 on the protein list) were observed. The biomarkers significant on both lists are potential hybrid markers. Thus, plasma hybrid markers have the potential to create a new class of early detection markers of cancers.
References
[1]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58, 71–96, doi:10.3322/CA.2007.0010.
[2]
Church, T.R.; Black, W.C.; Aberle, D.R.; Berg, C.D.; Clingan, K.L.; Duan, F.; Fagerstrom, R.M.; Gareen, I.F.; Gierada, D.S.; Jones, G.C.; et al. Results of initial low-dose computed tomographic screening for lung cancer. N. Engl. J. Med. 2013, 368, 1980–1991, doi:10.1056/NEJMoa1209120.
[3]
Brodersen, J.; Siersma, V.D. Long-term psychosocial consequences of false-positive screening mammography. Ann. Fam. Med. 2013, 11, 106–115, doi:10.1370/afm.1466.
[4]
Croswell, J.M.; Kramer, B.S.; Kreimer, A.R.; Prorok, P.C.; Xu, J.L.; Baker, S.G.; Fagerstrom, R.; Riley, T.L.; Clapp, J.D.; Berg, C.D.; et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann. Fam. Med. 2009, 7, 212–222, doi:10.1370/afm.942.
[5]
Weller, D.; Coleman, D.; Robertson, R.; Butler, P.; Melia, J.; Campbell, C.; Parker, R.; Patnick, J.; Moss, S. The UK colorectal cancer screening pilot: Results of the second round of screening in England. Br. J. Cancer 2007, 97, 1601–1605, doi:10.1038/sj.bjc.6604089.
[6]
Tumor markers. Available online: http://www.Cancer.Gov/cancertopics/factsheet/detection/tumor-markers (accessed on 5 November 2013).
[7]
Drucker, E.; Krapfenbauer, K. Pitfalls and limitations in translation from biomarker discovery to clinical utility in predictive and personalised medicine. EPMA J. 2013, 4, e7, doi:10.1186/1878-5085-4-7.
[8]
Issaq, H.J.; Waybright, T.J.; Veenstra, T.D. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods. Electrophoresis 2011, 32, 967–975, doi:10.1002/elps.201000588.
[9]
Hori, S.S.; Gambhir, S.S. Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci. Transl. Med. 2011, 3, 109ra116.
[10]
Poon, T.C.; Mok, T.S.; Chan, A.T.; Chan, C.M.; Leong, V.; Tsui, S.H.; Leung, T.W.; Wong, H.T.; Ho, S.K.; Johnson, P.J. Quantification and utility of monosialylated alpha-fetoprotein in the diagnosis of hepatocellular carcinoma with nondiagnostic serum total alpha-fetoprotein. Clin. Chem. 2002, 48, 1021–1027.
Kui Wong, N.; Easton, R.L.; Panico, M.; Sutton-Smith, M.; Morrison, J.C.; Lattanzio, F.A.; Morris, H.R.; Clark, G.F.; Dell, A.; Patankar, M.S. Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. J. Biol. Chem. 2003, 278, 28619–28634, doi:10.1074/jbc.M302741200.
[13]
Saeland, E.; Belo, A.I.; Mongera, S.; van Die, I.; Meijer, G.A.; van Kooyk, Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon cancer patients. Int. J. Cancer 2012, 131, 117–128, doi:10.1002/ijc.26354.
[14]
Hanisch, F.G.; Uhlenbruck, G.; Dienst, C. Structure of tumor-associated carbohydrate antigen CA 19-9 on human seminal-plasma glycoproteins from healthy donors. Eur. J. Biochem. 1984, 144, 467–473, doi:10.1111/j.1432-1033.1984.tb08489.x.
[15]
Gadroy, P.; Stridsberg, M.; Capon, C.; Michalski, J.C.; Strub, J.M.; van Dorsselaer, A.; Aunis, D.; Metz-Boutigue, M.H. Phosphorylation and O-glycosylation sites of human chromogranin a (CGA79-439) from urine of patients with carcinoid tumors. J. Biol. Chem. 1998, 273, 34087–34097, doi:10.1074/jbc.273.51.34087.
[16]
Wu, Y.M.; Liu, C.H.; Hu, R.H.; Huang, M.J.; Lee, J.J.; Chen, C.H.; Huang, J.; Lai, H.S.; Lee, P.H.; Hsu, W.M.; et al. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 2011, 71, 7270–7279, doi:10.1158/0008-5472.CAN-11-1161.
[17]
Liu, Y.C.; Yen, H.Y.; Chen, C.Y.; Chen, C.H.; Cheng, P.F.; Juan, Y.H.; Khoo, K.H.; Yu, C.J.; Yang, P.C.; Hsu, T.L.; et al. Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells. Proc. Natl. Acad. Sci. USA 2011, 108, 11332–11337, doi:10.1073/pnas.1107385108.
[18]
Drapkin, R.; von Horsten, H.H.; Lin, Y.; Mok, S.C.; Crum, C.P.; Welch, W.R.; Hecht, J.L. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005, 65, 2162–2169, doi:10.1158/0008-5472.CAN-04-3924.
[19]
Pabst, M.; Bondili, J.S.; Stadlmann, J.; Mach, L.; Altmann, F. Mass + retention time = structure: A strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. Anal. Chem. 2007, 79, 5051–5057, doi:10.1021/ac070363i.
[20]
Doherty, J.K.; Bond, C.; Jardim, A.; Adelman, J.P.; Clinton, G.M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. USA 1999, 96, 10869–10874, doi:10.1073/pnas.96.19.10869.
[21]
Majumder, S.; Brown, K.; Qiu, F.H.; Besmer, P. C-kit protein, a transmembrane kinase: Identification in tissues and characterization. Mol. Cell. Biol. 1988, 8, 4896–4903.
[22]
Meany, D.L.; Zhang, Z.; Sokoll, L.J.; Zhang, H.; Chan, D.W. Glycoproteomics for prostate cancer detection: Changes in serum PSA glycosylation patterns. J. Proteome Res. 2009, 8, 613–619, doi:10.1021/pr8007539.
[23]
Hakomori, S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv. Cancer Res. 1989, 52, 257–331.
[24]
Yang, S.X.; Pollock, H.G.; Rawitch, A.B. Glycosylation in human thyroglobulin: Location of the n-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch. Biochem. Biophys. 1996, 327, 61–70, doi:10.1006/abbi.1996.0093.
[25]
Wang, V.; Li, C.; Lin, M.; Welch, W.; Bell, D.; Wong, Y.F.; Berkowitz, R.; Mok, S.C.; Bandera, C.A. Ovarian cancer is a heterogeneous disease. Cancer Genet. Cytogenet. 2005, 161, 170–173, doi:10.1016/j.cancergencyto.2004.12.014.
[26]
Zhao, H.; Langerod, A.; Ji, Y.; Nowels, K.W.; Nesland, J.M.; Tibshirani, R.; Bukholm, I.K.; Karesen, R.; Botstein, D.; Borresen-Dale, A.L.; et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol. Biol. Cell. 2004, 15, 2523–2536, doi:10.1091/mbc.E03-11-0786.
[27]
Warnberg, F.; Nordgren, H.; Bergkvist, L.; Holmberg, L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Br. J. Cancer 2001, 85, 869–874, doi:10.1054/bjoc.2001.1995.
[28]
Shah, S.P.; Roth, A.; Goya, R.; Oloumi, A.; Ha, G.; Zhao, Y.; Turashvili, G.; Ding, J.; Tse, K.; Haffari, G.; et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012, 486, 395–399.
[29]
Kravchenko, J.; Akushevich, I.; Seewaldt, V.L.; Abernethy, A.P.; Lyerly, H.K. Breast cancer as heterogeneous disease: Contributing factors and carcinogenesis mechanisms. Breast Cancer Res. Treat. 2011, 128, 483–493, doi:10.1007/s10549-011-1347-z.
[30]
West, L.; Vidwans, S.J.; Campbell, N.P.; Shrager, J.; Simon, G.R.; Bueno, R.; Dennis, P.A.; Otterson, G.A.; Salgia, R. A novel classification of lung cancer into molecular subtypes. PLoS One 2012, 7, e31906, doi:10.1371/journal.pone.0031906.
[31]
Berek, J.S.; Bast, R.C., Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer 1995, 76, 2092–2096, doi:10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T.
[32]
Yedema, C.A.; Kenemans, P.; Wobbes, T.; Thomas, C.M.; Bon, G.G.; Mulder, C.; Voorhorst, F.J.; Verstraeten, A.A.; van Kamp, G.J.; Hilgers, J. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas. Tumor Biol. 1992, 13, 18–26, doi:10.1159/000217748.
[33]
Firpo, M.A.; Gay, D.Z.; Granger, S.R.; Scaife, C.L.; DiSario, J.A.; Boucher, K.M.; Mulvihill, S.J. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid a in a panel screen. World J. Surg. 2009, 33, 716–722, doi:10.1007/s00268-008-9853-9.
[34]
Wild, N.; Andres, H.; Rollinger, W.; Krause, F.; Dilba, P.; Tacke, M.; Karl, J. A combination of serum markers for the early detection of colorectal cancer. Clin. Cancer Res. 2010, 16, 6111–6121, doi:10.1158/1078-0432.CCR-10-0119.
[35]
Gormally, E.; Caboux, E.; Vineis, P.; Hainaut, P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: Practical aspects and biological significance. Mutat. Res. 2007, 635, 105–117, doi:10.1016/j.mrrev.2006.11.002.
[36]
deVos, T.; Tetzner, R.; Model, F.; Weiss, G.; Schuster, M.; Distler, J.; Steiger, K.V.; Grutzmann, R.; Pilarsky, C.; Habermann, J.K.; et al. Circulating methylated sept9 DNA in plasma is a biomarker for colorectal cancer. Clin. Chem. 2009, 55, 1337–1346, doi:10.1373/clinchem.2008.115808.
[37]
Kosaka, N.; Iguchi, H.; Ochiya, T. Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101, 2087–2092, doi:10.1111/j.1349-7006.2010.01650.x.
[38]
Li, T.; Kung, H.J.; Mack, P.C.; Gandara, D.R. Genotyping and genomic profiling of non-small-cell lung cancer: Implications for current and future therapies. J. Clin. Oncol. 2013, 31, 1039–1049, doi:10.1200/JCO.2012.45.3753.
[39]
Anderson, N.L.; Anderson, N.G. The human plasma proteome: History, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845–867, doi:10.1074/mcp.R200007-MCP200.
[40]
Catalona, W.J.; Richie, J.P.; deKernion, J.B.; Ahmann, F.R.; Ratliff, T.L.; Dalkin, B.L.; Kavoussi, L.R.; MacFarlane, M.T.; Southwick, P.C. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: Receiver operating characteristic curves. J. Urol. 1994, 152, 2031–2036.
[41]
Schroder, F.H.; van der Cruijsen-Koeter, I.; de Koning, H.J.; Vis, A.N.; Hoedemaeker, R.F.; Kranse, R. Prostate cancer detection at low prostate specific antigen. J. Urol. 2000, 163, 806–812, doi:10.1016/S0022-5347(05)67809-3.
[42]
Negishi, Y.; Furukawa, T.; Oka, T.; Sakamoto, M.; Hirata, T.; Okabe, K.; Matayoshi, K.; Akiya, K.; Soma, H. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma. Gynecol. Obstet. Invest. 1987, 23, 200–207, doi:10.1159/000298862.
[43]
Coghlin, C.; Murray, G.I. Progress in the identification of plasma biomarkers of colorectal cancer. Proteomics 2013, 13, 2227–2228, doi:10.1002/pmic.201300245.
[44]
Rho, J.H.; Lampe, P.D. High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays. J. Proteome Res. 2013, 12, 2311–2320, doi:10.1021/pr4001674.
[45]
Soussi, T. P53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res. 2000, 60, 1777–1788.
[46]
Von Mensdorff-Pouilly, S.; Petrakou, E.; Kenemans, P.; van Uffelen, K.; Verstraeten, A.A.; Snijdewint, F.G.; van Kamp, G.J.; Schol, D.J.; Reis, C.A.; Price, M.R.; et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int. J. Cancer 2000, 86, 702–712, doi:10.1002/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1.
[47]
Ulanet, D.B.; Torbenson, M.; Dang, C.V.; Casciola-Rosen, L.; Rosen, A. Unique conformation of cancer autoantigen b23 in hepatoma: A mechanism for specificity in the autoimmune response. Proc. Natl. Acad. Sci. USA 2003, 100, 12361–12366, doi:10.1073/pnas.2035245100.
[48]
Fourneau, J.M.; Bach, J.M.; van Endert, P.M.; Bach, J.F. The elusive case for a role of mimicry in autoimmune diseases. Mol. Immunol. 2004, 40, 1095–1102, doi:10.1016/j.molimm.2003.11.011.
[49]
Casciola-Rosen, L.; Andrade, F.; Ulanet, D.; Wong, W.B.; Rosen, A. Cleavage by granzyme b is strongly predictive of autoantigen status: Implications for initiation of autoimmunity. J. Exp. Med. 1999, 190, 815–826, doi:10.1084/jem.190.6.815.
[50]
Nozawa, K.; Fritzler, M.J.; Chan, E.K. Unique and shared features of Golgi complex autoantigens. Autoimmun. Rev. 2005, 4, 35–41, doi:10.1016/j.autrev.2004.06.002.
[51]
Rho, J.H.; Zhang, W.; Murali, M.; Roehrl, M.H.; Wang, J.Y. Human proteins with affinity for dermatan sulfate have the propensity to become autoantigens. Am. J. Pathol. 2011, 178, 2177–2190, doi:10.1016/j.ajpath.2011.01.031.
[52]
Russo, N.; Wang, X.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R.C.; Tsodikov, A.; Duffy, S.; et al. A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene 2011, 32, 5026–5037.
[53]
Imahayashi, S.; Ichiyoshi, Y.; Yoshino, I.; Eifuku, R.; Takenoyama, M.; Yasumoto, K. Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer. Cancer Invest. 2000, 18, 530–536, doi:10.3109/07357900009012192.
[54]
Lim, K.H.; Telisinghe, P.U.; Abdullah, M.S.; Ramasamy, R. Possible significance of differences in proportions of cytotoxic T cells and B-lineage cells in the tumour-infiltrating lymphocytes of typical and atypical medullary carcinomas of the breast. Cancer Immun. 2010, 10, e3.
[55]
Milne, K.; Kobel, M.; Kalloger, S.E.; Barnes, R.O.; Gao, D.; Gilks, C.B.; Watson, P.H.; Nelson, B.H. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 2009, 4, e6412.
[56]
Nedergaard, B.S.; Ladekarl, M.; Nyengaard, J.R.; Nielsen, K. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years. Gynecol. Oncol. 2008, 108, 106–111, doi:10.1016/j.ygyno.2007.08.089.
[57]
Deschoolmeester, V.; Baay, M.; Van Marck, E.; Weyler, J.; Vermeulen, P.; Lardon, F.; Vermorken, J.B. Tumor infiltrating lymphocytes: An intriguing player in the survival of colorectal cancer patients. BMC Immunol. 2010, 11, e19, doi:10.1186/1471-2172-11-19.
[58]
Al-Shibli, K.I.; Donnem, T.; Al-Saad, S.; Persson, M.; Bremnes, R.M.; Busund, L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin. Cancer Res. 2008, 14, 5220–5227, doi:10.1158/1078-0432.CCR-08-0133.
[59]
Riemann, D.; Wenzel, K.; Schulz, T.; Hofmann, S.; Neef, H.; Lautenschlager, C.; Langner, J. Phenotypic analysis of T lymphocytes isolated from non-small-cell lung cancer. Int. Arch. Allergy Immunol. 1997, 114, 38–45, doi:10.1159/000237640.
[60]
Nelson, B.H. CD20+ B cells: The other tumor-infiltrating lymphocytes. J. Immunol. 2010, 185, 4977–4982, doi:10.4049/jimmunol.1001323.
[61]
Lubin, R.; Zalcman, G.; Bouchet, L.; Tredanel, J.; Legros, Y.; Cazals, D.; Hirsch, A.; Soussi, T. Serum p53 antibodies as early markers of lung cancer. Nat. Med. 1995, 1, 701–702, doi:10.1038/nm0795-701.
[62]
Pedersen, J.W.; Gentry-Maharaj, A.; Nostdal, A.; Fourkala, E.O.; Dawnay, A.; Burnell, M.; Zaikin, A.; Burchell, J.; Papadimitriou, J.T.; Clausen, H.; et al. Cancer associated auto-antibodies to MUC1 and MUC4—A blinded case control study of colorectal cancer in UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Int. J. Cancer 2013, doi:10.1002/ijc.28538.
[63]
Apweiler, R.; Hermjakob, H.; Sharon, N. On the frequency of protein glycosylation, as deduced from analysis of the swiss-prot database. Biochim. Biophys. Acta 1999, 1473, 4–8.
[64]
Varki, A.; Kannagi, R.; Toole, B.P. Glycosylation changes in cancer. In Essentials of Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., Etzler, M.E., Eds.; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, USA, 2009.
[65]
Brockhausen, I. Mucin-type o-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 2006, 7, 599–604, doi:10.1038/sj.embor.7400705.
[66]
Adamczyk, B.; Tharmalingam, T.; Rudd, P.M. Glycans as cancer biomarkers. Biochim. Biophys. Acta 2012, 1820, 1347–1353, doi:10.1016/j.bbagen.2011.12.001.
[67]
Reis, C.A.; Osorio, H.; Silva, L.; Gomes, C.; David, L. Alterations in glycosylation as biomarkers for cancer detection. J. Clin. Pathol. 2010, 63, 322–329.
Wada, Y.; Azadi, P.; Costello, C.E.; Dell, A.; Dwek, R.A.; Geyer, H.; Geyer, R.; Kakehi, K.; Karlsson, N.G.; Kato, K.; et al. Comparison of the methods for profiling glycoprotein glycans—HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study. Glycobiology 2007, 17, 411–422, doi:10.1093/glycob/cwl086.
[70]
Yue, T.; Partyka, K.; Maupin, K.A.; Hurley, M.; Andrews, P.; Kaul, K.; Moser, A.J.; Zeh, H.; Brand, R.E.; Haab, B.B. Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases. Proteomics 2011, 11, 3665–3674, doi:10.1002/pmic.201000827.
[71]
Hashii, N.; Kawasaki, N.; Itoh, S.; Nakajima, Y.; Harazono, A.; Kawanishi, T.; Yamaguchi, T. Identification of glycoproteins carrying a target glycan-motif by liquid chromatography/multiple-stage mass spectrometry: Identification of Lewis x-conjugated glycoproteins in mouse kidney. J. Proteome Res. 2009, 8, 3415–3429, doi:10.1021/pr9000527.
[72]
Haab, B.B.; Yue, T. High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. Methods Mol. Biol. 2011, 785, 223–236, doi:10.1007/978-1-61779-286-1_15.
[73]
Yue, T.; Goldstein, I.J.; Hollingsworth, M.A.; Kaul, K.; Brand, R.E.; Haab, B.B. The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol. Cell. Proteomics 2009, 8, 1697–1707, doi:10.1074/mcp.M900135-MCP200.
[74]
Wu, Y.M.; Nowack, D.D.; Omenn, G.S.; Haab, B.B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J. Proteome Res. 2009, 8, 1876–1886, doi:10.1021/pr8008379.
[75]
Yue, T.; Maupin, K.A.; Fallon, B.; Li, L.; Partyka, K.; Anderson, M.A.; Brenner, D.E.; Kaul, K.; Zeh, H.; Moser, A.J.; et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One 2011, 6, e29180, doi:10.1371/journal.pone.0029180.
[76]
Rho, J.H.; Mead, J.R.; Wright, W.S.; Brenner, D.E.; Stave, J.W.; Gildersleeve, J.C.; Lampe, P.D. Discovery of sialyl Lewis A and Lewis X modified protein cancer biomarkers using high density antibody arrays. J. Proteomics 2014, 96, 291–299, doi:10.1016/j.jprot.2013.10.030.
[77]
Loch, C.M.; Ramirez, A.B.; Liu, Y.; Sather, C.L.; Delrow, J.J.; Scholler, N.; Garvik, B.M.; Urban, N.D.; McIntosh, M.W.; Lampe, P.D. Use of high density antibody arrays to validate and discover cancer serum biomarkers. Mol. Oncol. 2007, 1, 313–320.
[78]
Rangiah, K.; Tippornwong, M.; Sangar, V.; Austin, D.; Tetreault, M.P.; Rustgi, A.K.; Blair, I.A.; Yu, K.H. Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer. J. Proteome Res. 2009, 8, 5153–5164, doi:10.1021/pr900518v.
[79]
Stenman, U.H.; Leinonen, J.; Alfthan, H.; Rannikko, S.; Tuhkanen, K.; Alfthan, O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991, 51, 222–226.
[80]
Beneduce, L.; Prayer-Galetti, T.; Giustinian, A.M.; Gallotta, A.; Betto, G.; Pagano, F.; Fassina, G. Detection of prostate-specific antigen coupled to immunoglobulin m in prostate cancer patients. Cancer Detect. Prev. 2007, 31, 402–407, doi:10.1016/j.cdp.2007.10.005.
[81]
Weiss, L.; Haydock, K.; Pickren, J.W.; Lane, W.W. Organ vascularity and metastatic frequency. Am. J. Pathol. 1980, 101, 101–113.
[82]
Hittelet, A.; Camby, I.; Nagy, N.; Legendre, H.; Bronckart, Y.; Decaestecker, C.; Kaltner, H.; Nifant’ev, N.E.; Bovin, N.V.; Pector, J.C.; et al. Binding sites for Lewis antigens are expressed by human colon cancer cells and negatively affect their migration. Lab. Invest. 2003, 83, 777–787, doi:10.1097/01.LAB.0000073129.62433.39.
[83]
Koh, Y.W.; Lee, H.J.; Ahn, J.H.; Lee, J.W.; Gong, G. Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer. Am. J. Clin. Pathol. 2013, 139, 746–753, doi:10.1309/AJCP2E6QNDIDPTTC.
[84]
Remmers, N.; Anderson, J.M.; Linde, E.M.; DiMaio, D.J.; Lazenby, A.J.; Wandall, H.H.; Mandel, U.; Clausen, H.; Yu, F.; Hollingsworth, M.A. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin. Cancer Res. 2013, 19, 1981–1993, doi:10.1158/1078-0432.CCR-12-2662.
